(NASDAQ: HROW) Harrow's forecast annual revenue growth rate of 29.36% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 135.86%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.83%.
Harrow's revenue in 2025 is $250,042,000.On average, 10 Wall Street analysts forecast HROW's revenue for 2025 to be $10,273,448,713, with the lowest HROW revenue forecast at $9,586,033,585, and the highest HROW revenue forecast at $10,703,083,168. On average, 10 Wall Street analysts forecast HROW's revenue for 2026 to be $14,730,165,433, with the lowest HROW revenue forecast at $13,044,961,321, and the highest HROW revenue forecast at $17,239,823,248.
In 2027, HROW is forecast to generate $20,261,338,664 in revenue, with the lowest revenue forecast at $17,175,748,454 and the highest revenue forecast at $23,325,447,150.